Stock A245620 EONE DIAGNOMICS GENOME CENTER CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Eone Diagnomics Genome Center Co., Ltd. Stock

Equities

A245620

KR7245620000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-04 pm EDT 		5-day change 1st Jan Change
415 KRW -5.25% Intraday chart for Eone Diagnomics Genome Center Co., Ltd. 0.00% -0.72%
Apr. 16 Eone Diagnomics Genome Center Co., Ltd.(KOSDAQ:A245620) dropped from S&P Global BMI Index CI
Apr. 08 Eone Diagnomics Genome Center Co., Ltd. announced that it has received KRW 20 billion in funding CI

Financials

Sales 2022 94.24B 68.42M Sales 2023 88.46B 64.22M Capitalization 48.88B 35.48M
Net income 2022 -29.86B -21.68M Net income 2023 -33.03B -23.98M EV / Sales 2022 2.49 x
Net Debt 2022 78.25B 56.81M Net Debt 2023 61.28B 44.49M EV / Sales 2023 1.25 x
P/E ratio 2022
-5.15 x
P/E ratio 2023
-1.14 x
Employees 103
Yield 2022 *
-
Yield 2023
-
Free-Float 86.91%
More Fundamentals * Assessed data

Chart Eone Diagnomics Genome Center Co., Ltd.

Dynamic Chart

Latest news about Eone Diagnomics Genome Center Co., Ltd.

Eone Diagnomics Genome Center Co., Ltd.(KOSDAQ:A245620) dropped from S&P Global BMI Index CI
Eone Diagnomics Genome Center Co., Ltd. announced that it has received KRW 20 billion in funding CI
Eone Diagnomics Genome Center Co., Ltd. announced that it expects to receive KRW 20 billion in funding CI
Eone Diagnomics Genome Center Co., Ltd. acquired GDxLab, INC. CI
Eone Diagnomics Genome Center to Raise 89.4 Billion Won via Stock Sale MT
Eone Diagnomics Genome Center Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Eone Diagnomics Genome Center Co., Ltd. announced that it has received KRW 6 billion in funding from Shinhan Financial Investment Co., Ltd., Samsung Securities Co., Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd. CI
Eone Diagnomics Genome Center Co., Ltd. announced that it expects to receive KRW 6 billion in funding from Shinhan Financial Investment Co., Ltd., Samsung Securities Co., Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd. CI
MarketScreener's World Press Review : April 11, 2022 Our Logo
Eone Diagnomics Genome Center Co., Ltd. announced that it has received KRW 10 billion in funding from Korea Investment Hanwha Healthcare Private Equity Fund Co. Ltd CI
Eone Diagnomics Genome Center Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Korea Investment Hanwha Healthcare Private Equity Fund Co. Ltd CI
Eone Diagnomics Genome Center Co., Ltd. announced that it has received KRW 30 billion in funding CI
Eone Diagnomics Genome Center Co., Ltd. announced that it expects to receive KRW 30 billion in funding CI
Eone Diagnomics Genome Center Co., Ltd. acquired Natural Life Nutrition Inc. CI
Maple Holdings Co., Ltd. announced that it has received KRW 25 billion in funding from Eone Diagnomics Genome Center Co., Ltd. CI
More news

News in other languages on Eone Diagnomics Genome Center Co., Ltd.

BASF SE : En el ojo de la tormenta
BASF SE : Dans l'œil du cyclone
EON : pas de prolongation pour la centrale nucléaire
Planète Bourse : La revue de presse du lundi 11 avril 2022
FORTESCUE, EON : remplacer le gaz russe par de l'hydrogène australien
More news

Quotes and Performance

1 day-5.25%
Current month-12.08%
1 month-13.54%
3 months+7.24%
6 months-42.92%
Current year-0.72%
More quotes

Highs and lows

1 month
401.00
Extreme 401
569.00
Current year
349.00
Extreme 349
798.00
1 year
349.00
Extreme 349
2 075.00
3 years
349.00
Extreme 349
5 980.00
5 years
349.00
Extreme 349
11 925.00
10 years
349.00
Extreme 349
11 925.00
More quotes

Managers and Directors - Eone Diagnomics Genome Center Co., Ltd.

Managers TitleAgeSince
Shang Cheol Shin CEO
 Chief Executive Officer - -
Min-Seob Lee CEO
 Chief Executive Officer 58 13-01-31
Sam Martin PRN
 Corporate Officer/Principal 46 22-09-12
Members of the board TitleAgeSince
Gyu-Yeon Lee BRD
 Director/Board Member 60 -
Min-Seob Lee CEO
 Chief Executive Officer 58 13-01-31
Sung Ho Kim BRD
 Director/Board Member - -
More insiders

Company Profile

Eone Diagnomics Genome Center Co., Ltd. is a Korea-based company engaged in genetic analysis business. The Company is engaged in non-invasive prenatal tests (NIPT), newborn screening tests, ophthalmologist specialist genome analysis tests, customized disease prediction tests, and direct to consumer (DTC) genetic tests, among others. In addition, the Company is developing genome-related software.
Sector
Pharmaceuticals
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
EONE DIAGNOMICS GENOME CENTER CO., LTD. Stock Eone Diagnomics Genome Center Co., Ltd.
-0.72% 41.63M
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+2.01% 25.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.40% 8.16B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+2.20% 8.36B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-23.25% 7.69B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+1.53% 4.53B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+21.26% 4.47B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.46% 3.99B
GALENICA AG Stock Galenica AG
-2.47% 3.88B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.68% 3.66B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. A245620 Stock